anti-CD19 CAR T-cell therapy rapamycin-treated (Rapa Therapeutics/University of Toronto/Medical College of Wisconsin)

N/A

Report date: 2025/01/26 18:16:24

Base Information

Drug Nameanti-CD19 CAR T-cell therapy rapamycin-treated (Rapa Therapeutics/University of Toronto/Medical College of Wisconsin)
Drug Alias NameCAR-modified Th1/Tc1-polarized T-Rapa Cells (Rapa Therapeutics/University of Toronto/Medical College of Wisconsin)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRapa Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesRapa Therapeutics LlcUniversity of TorontoThe Medical College Of Wisconsin Nonprofit
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A